These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 19656807)

  • 1. Budget impact analysis of chemoprevention of breast cancer with tamoxifen and raloxifene among high-risk women in Japan.
    Kondo M; Hoshi SL; Toi M
    Jpn J Clin Oncol; 2009 Nov; 39(11):767-70. PubMed ID: 19656807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemoprevention of breast cancer.
    Dalton RR; Kallab AM
    South Med J; 2001 Jan; 94(1):7-15. PubMed ID: 11213947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Task force cautious about chemoprevention. Official guidelines are out about taking tamoxifen and raloxifene to prevent breast cancer. These drugs can help, but they aren't for everyone.
    Harv Womens Health Watch; 2002 Oct; 10(2):1-2. PubMed ID: 12393316
    [No Abstract]   [Full Text] [Related]  

  • 4. [Breakthrough in breast cancer chemoprevention].
    Kahán Z; Thurzó L
    Orv Hetil; 2003 Mar; 144(13):597-603. PubMed ID: 12728784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tamoxifen and raloxifene may benefit women at high risk for breast cancer.
    Rollins G
    Rep Med Guidel Outcomes Res; 2002 Jul; 13(14):1-2, 5. PubMed ID: 12518771
    [No Abstract]   [Full Text] [Related]  

  • 6. Chemoprevention: drug pricing and mortality: the case of tamoxifen.
    Melnikow J; Kuenneth C; Helms LJ; Barnato A; Kuppermann M; Birch S; Nuovo J
    Cancer; 2006 Sep; 107(5):950-8. PubMed ID: 16865680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted antiestrogens for the prevention of breast cancer.
    Bentrem DJ; Jordan VC
    Oncol Res; 1999; 11(9):401-7. PubMed ID: 10821534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The STAR trial: evidence for raloxifene as a breast cancer risk reduction agent for postmenopausal women.
    Bevers TB
    J Natl Compr Canc Netw; 2007 Sep; 5(8):719-24. PubMed ID: 17927929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Chemoprevention of breast cancer. Clinical trials in pharmacological prevention].
    Ricart JJ
    Medicina (B Aires); 2004; 64(1):66-72. PubMed ID: 15034961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer.
    Ganz PA; Land SR
    Menopause; 2008; 15(4 Suppl):797-803. PubMed ID: 18596601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemoprevention of breast cancer.
    Castrellon AB; Glück S
    Expert Rev Anticancer Ther; 2008 Mar; 8(3):443-52. PubMed ID: 18366291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tamoxifen for breast cancer prevention: a framework for clinical decisions.
    Cykert S; Phifer N; Hansen C
    Obstet Gynecol; 2004 Sep; 104(3):433-42. PubMed ID: 15339751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Chemoprevention of breast cancer. Impact of a new therapeutic strategy].
    Kattan J; Ghosn M
    J Med Liban; 1999; 47(5):284-5. PubMed ID: 10887527
    [No Abstract]   [Full Text] [Related]  

  • 14. Progress in chemoprevention of breast cancer.
    Serrano D; Perego E; Costa A; Decensi A
    Crit Rev Oncol Hematol; 2004 Feb; 49(2):109-17. PubMed ID: 15012972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast cancer risk in primary care: implications for chemoprevention.
    Lewis CL; Kinsinger LS; Harris RP; Schwartz RJ
    Arch Intern Med; 2004 Sep; 164(17):1897-903. PubMed ID: 15451765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atypia in random periareolar fine-needle aspiration affects the decision of women at high risk to take tamoxifen for breast cancer chemoprevention.
    Goldenberg VK; Seewaldt VL; Scott V; Bean GR; Broadwater G; Fabian C; Kimler B; Zalles C; Lipkus IM
    Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):1032-4. PubMed ID: 17507634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of breast cancer risk assessment techniques: a cost-effectiveness analysis.
    Ozanne EM; Esserman LJ
    Cancer Epidemiol Biomarkers Prev; 2004 Dec; 13(12):2043-52. PubMed ID: 15598759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Raloxifene prevails in STAR trial, may face easier road to acceptance than previous drugs.
    Vastag B
    J Natl Cancer Inst; 2006 Jun; 98(11):733-5. PubMed ID: 16757696
    [No Abstract]   [Full Text] [Related]  

  • 19. Breast carcinoma chemoprevention in the community setting. Estimating risks and benefits.
    Brewster AM; Christo DK; Lai H; Helzlsouer K
    Cancer; 2005 Mar; 103(6):1147-53. PubMed ID: 15674856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Raloxifene works as well as tamoxifen in preventing invasive breast cancer.
    Mayo Clin Womens Healthsource; 2006 Oct; 10(10):3. PubMed ID: 16977270
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.